Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dutogliptin - Recardio

Drug Profile

Dutogliptin - Recardio

Alternative Names: Dutogliptin tartrate; PHX-1149; PHX1149T; REC-01

Latest Information Update: 19 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phenomix Corporation
  • Developer Phenomix Corporation; RECARDIO
  • Class Antihyperglycaemics; Ischaemic heart disorder therapies; Pyrrolidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Myocardial infarction
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 25 Aug 2018 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Myocardial infarction (MI) presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2018)
  • 01 Aug 2018 Phase-II clinical trials in Myocardial infarction (Combination therapy) in USA, United Kingdom, Scotland, Poland, Netherlands, Hungary, Bulgaria, Belgium, Austria (SC) (NCT03486080)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top